Conduct Early-Phase Studies To Improve Manufacturability And Mitigate Risk

Creating effective, scalable manufacturing strategies for adeno-associated virus (AAV) therapies means sponsors and contract development and manufacturing organizations (CDMOs) must identify creative and collaborative solutions in the early phases of development. In a recent webinar hosted by FUJIFILM Diosynth Biotechnologies (FDB), Ian Goodwin, Director of CMC Program Design, provided his expert insight into the benefits of implementing early-phase studies like candidate screening and feasibility assessments for AAV manufacturing. In the post-webinar Q&A session, Goodwin tackled listener questions on manufacturability vs. clinical efficacy, regulatory support, and more. Download the full Q&A article to learn more about the impact of working with a CDMO that provides support, transparency, and a significant amount of experience to manufacture your AAV therapeutic.